Gastric Cancer pp 193-201 | Cite as

Prevention Strategy for Gastric Cancer

  • Osamu Handa
  • Yuji NaitoEmail author


In Japan, the major cause of gastric cancer is Helicobacter pylori infection. Therefore, targeting H. pylori eradication is considered an effective strategy to prevent gastric carcinogenesis. However, the prevention strategy should be decided based on the risk of individual patients. The risk of gastric cancer has been reported to depend on the severity of atrophic mucosa caused by Helicobacter pylori, and the earlier H. pylori eradication has been thought to be more effective in the prevention of future gastric carcinogenesis. Consequently, there are several “screen-and-treat” projects at the prefectural level in Japan for junior high and high school students. On the contrary to the high-risk group, the severity of gastric mucosal atrophy is much severer than the younger generation, and follow-up surveillance for gastric cancer is more important in addition to H. pylori eradication.


Helicobacter pylori Younger generation Student Screen and treat Gastric cancer 


  1. 1.
    Suzuki H, Mori H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol. 2018;53(3):354–61.CrossRefGoogle Scholar
  2. 2.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefGoogle Scholar
  3. 3.
    Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16(6):415–9.CrossRefGoogle Scholar
  4. 4.
    Ono S, Kato M, Suzuki M, Ishigaki S, Takahashi M, Haneda M, Mabe K, Shimizu Y. Frequency of Helicobacter pylori-negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic and serological atrophy. Digestion. 2012;86(1):59–65.CrossRefGoogle Scholar
  5. 5.
    Okuda M, Osaki T, Lin Y, Yonezawa H, Maekawa K, Kamiya S, Fukuda Y, Kikuchi S. Low prevalence and incidence of Helicobacter pylori infection in children: a population-based study in Japan. Helicobacter. 2015;20(2):133–8.CrossRefGoogle Scholar
  6. 6.
    Konno M, Yokota S, Suga T, Takahashi M, Sato K, Fujii N. Predominance of mother-to-child transmission of Helicobacter pylori infection detected by random amplified polymorphic DNA fingerprinting analysis in Japanese families. Pediatr Infect Dis J. 2008;27(11):999–1003.CrossRefGoogle Scholar
  7. 7.
    Osaki T, Okuda M, Ueda J, Konno M, Yonezawa H, Hojo F, Yagyu K, Lin Y, Fukuda Y, Kikuchi S, et al. Multilocus sequence typing of DNA from faecal specimens for the analysis of intra-familial transmission of Helicobacter pylori. J Med Microbiol. 2013;62(Pt 5):761–5.CrossRefGoogle Scholar
  8. 8.
    Okuda M, Miyashiro E, Booka M, Tsuji T, Nakazawa T. Helicobacter pylori colonization in the first 3 years of life in Japanese children. Helicobacter. 2007;12(4):324–7.CrossRefGoogle Scholar
  9. 9.
    Rowland M, Daly L, Vaughan M, Higgins A, Bourke B, Drumm B. Age-specific incidence of Helicobacter pylori. Gastroenterology. 2006;130(1):65–72, quiz 211.CrossRefGoogle Scholar
  10. 10.
    Adamu MA, Weck MN, Gao L, Brenner H. Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies. Eur J Epidemiol. 2010;25(7):439–48.CrossRefGoogle Scholar
  11. 11.
    Jaskiewicz K, Louwrens HD. Chronic atrophic gastritis in a population at risk for gastric carcinoma. Anticancer Res. 1991;11(2):835–9.PubMedGoogle Scholar
  12. 12.
    Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–9.CrossRefGoogle Scholar
  13. 13.
    Take S, Mizuno M, Ishiki K, Yoshida T, Ohara N, Yokota K, Oguma K, Okada H, Yamamoto K. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol. 2011;46(3):318–24.CrossRefGoogle Scholar
  14. 14.
    Ueda M, Kikuchi S, Kasugai T, Shunichi T, Miyake C. Helicobacter pylori risk associated with childhood home environment. Cancer Sci. 2003;94(10):914–8.CrossRefGoogle Scholar
  15. 15.
    Asaka M, Kimura T, Kudo M, Takeda H, Mitani S, Miyazaki T, Miki K, Graham DY. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology. 1992;102(3):760–6.CrossRefGoogle Scholar
  16. 16.
    Ueda J, Gosho M, Inui Y, Matsuda T, Sakakibara M, Mabe K, Nakajima S, Shimoyama T, Yasuda M, Kawai T, et al. Prevalence of Helicobacter pylori infection by birth year and geographic area in Japan. Helicobacter. 2014;19(2):105–10.CrossRefGoogle Scholar
  17. 17.
    Rowland M, Kumar D, Daly L, O’Connor P, Vaughan D, Drumm B. Low rates of Helicobacter pylori reinfection in children. Gastroenterology. 1999;117(2):336–41.CrossRefGoogle Scholar
  18. 18.
    Kato S, Abukawa D, Furuyama N, Iinuma K. Helicobacter pylori reinfection rates in children after eradication therapy. J Pediatr Gastroenterol Nutr. 1998;27(5):543–6.CrossRefGoogle Scholar
  19. 19.
    Halitim F, Vincent P, Michaud L, Kalach N, Guimber D, Boman F, Turck D, Gottrand F. High rate of Helicobacter pylori reinfection in children and adolescents. Helicobacter. 2006;11(3):168–72.CrossRefGoogle Scholar
  20. 20.
    Okuda M, Miyashiro E, Koike M, Tanaka T, Bouoka M, Okuda S, Yoshikawa N. Serodiagnosis of Helicobacter pylori infection is not accurate for children aged below 10. Pediatr Int. 2002;44(4):387–90.CrossRefGoogle Scholar
  21. 21.
    Yoshimura N, Tajiri H, Sawada A, Kozaiwa K, Ida S, Fujisawa T, Konno M, Kato S. A 13C-urea breath test in children with helicobacter pylori infection: assessment of eradication therapy and follow-up after treatment. J Gastroenterol. 2001;36(9):606–11.CrossRefGoogle Scholar
  22. 22.
    Kato S, Ozawa K, Konno M, Tajiri H, Yoshimura N, Shimizu T, Fujisawa T, Abukawa D, Minoura T, Iinuma K. Diagnostic accuracy of the 13C-urea breath test for childhood Helicobacter pylori infection: a multicenter Japanese study. Am J Gastroenterol. 2002;97(7):1668–73.CrossRefGoogle Scholar
  23. 23.
    Mabe K, Kikuchi S, Okuda M, Takamasa M, Kato M, Asaka M. Diagnostic accuracy of urine Helicobacter pylori antibody test in junior and senior high school students in Japan. Helicobacter. 2017;22(1). Epub 2016 Jul 11.CrossRefGoogle Scholar
  24. 24.
    Shimoyama T. Stool antigen tests for the management of Helicobacter pylori infection. World J Gastroenterol. 2013;19(45):8188–91.CrossRefGoogle Scholar
  25. 25.
    Okamura T, Suga T, Nagaya T, Arakura N, Matsumoto T, Nakayama Y, Tanaka E. Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multi-generational comparison. Helicobacter. 2014;19(3):214–20.CrossRefGoogle Scholar
  26. 26.
    Sasaki M, Ogasawara N, Utsumi K, Kawamura N, Kamiya T, Kataoka H, Tanida S, Mizoshita T, Kasugai K, Joh T. Changes in 12-year first-line eradication rate of Helicobacter pylori based on triple therapy with proton pump inhibitor, amoxicillin and clarithromycin. J Clin Biochem Nutr. 2010;47(1):53–8.CrossRefGoogle Scholar
  27. 27.
    Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439–46.CrossRefGoogle Scholar
  28. 28.
    Kusano C, Gotoda T, Suzuki S, Ikehara H, Moriyama M. Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children. J Gastroenterol. 2018;53(6):718–24.CrossRefGoogle Scholar
  29. 29.
    Li WQ, Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, Liu WD, Hu Y, Han ZX, et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J Natl Cancer Inst. 2014;106(7):dju352.CrossRefGoogle Scholar
  30. 30.
    Take S, Mizuno M, Ishiki K, Hamada F, Yoshida T, Yokota K, Okada H, Yamamoto K. Seventeen-year effects of eradicating Helicobacter pylori on the prevention of gastric cancer in patients with peptic ulcer; a prospective cohort study. J Gastroenterol. 2015;50(6):638–44.CrossRefGoogle Scholar
  31. 31.
    Majima A, Handa O, Naito Y, Dohi O, Okayama T, Yoshida N, Kamada K, Katada K, Uchiyama K, Ishikawa T, et al. Early-stage gastric cancer can be found in improved atrophic mucosa over time from successful Helicobacter pylori eradication. Digestion. 2017;95(3):194–200.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Molecular Gastroenterology and HepatologyKyoto Prefectural University of MedicineKyotoJapan

Personalised recommendations